Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

BACKGROUND: In neuroblastoma, genetic alterations in ATRX, define a distinct poor outcome patient subgroup. Despite the need for new therapies, there is a lack of available models and a dearth of pre-clinical research. METHODS: To evaluate the impact of ATRX loss of function (LoF) in neuroblastoma,...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Sally L, Lorenzi, Federica, King, David, Hartlieb, Sabine, Campbell, James, Pemberton, Helen, Toprak, Umut H, Barker, Karen, Tall, Jennifer, da Costa, Barbara Martins, van den Boogaard, Marlinde L, Dolman, M Emmy M, Molenaar, Jan J, Bryant, Helen E, Westermann, Frank, Lord, Christopher J, Chesler, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452577/
https://www.ncbi.nlm.nih.gov/pubmed/32846370
http://dx.doi.org/10.1016/j.ebiom.2020.102971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452577/
https://www.ncbi.nlm.nih.gov/pubmed/32846370
http://dx.doi.org/10.1016/j.ebiom.2020.102971

Ejemplares similares